Fase 2-platformsundersøgelse af nye immunterapikombinationer hos deltagere med tidligere ubehandlet, avanceret/metastatisk ikke-småcellet lungekræft
Et fase 2, randomiseret, åbent platformsstudie, der anvender en masterprotokol til at evaluere nye immunterapikombinationer hos deltagere med tidligere ubehandlet, lokalt avanceret/metastatisk, programmeret dødsligand 1-selekteret ikke-småcellet lungekræft
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, Argentina, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
- GSK Investigational Site
-
Florida, Argentina, 1602
- GSK Investigational Site
-
Mar del Plata, Argentina, 7600
- GSK Investigational Site
-
San Juan, Argentina, J5402DIL
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Wilrijk, Belgien, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- GSK Investigational Site
-
Porto Alegre, Brasilien, 90610-000
- GSK Investigational Site
-
São Paulo, Brasilien, 01246-000
- GSK Investigational Site
-
Vitória, Brasilien, 29043-260
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, Det Forenede Kongerige, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, Det Forenede Kongerige, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Det Forenede Kongerige, HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Tampere, Finland, 33520
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
Vaasa, Finland, 65130
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, Forenede Arabiske Emirater
- GSK Investigational Site
-
Abu Dhabi, Forenede Arabiske Emirater, 51900
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, Forenede Stater, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Frankrig, 33076
- GSK Investigational Site
-
Caen, Frankrig, 14033
- GSK Investigational Site
-
Marseille, Frankrig, 13009
- GSK Investigational Site
-
Quimper, Frankrig, 29107
- GSK Investigational Site
-
Strasbourg, Frankrig, 67091
- GSK Investigational Site
-
-
-
-
-
Athens, Grækenland, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, Grækenland, 57001
- GSK Investigational Site
-
Thessaloniki, Grækenland, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, Grækenland, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, Grækenland, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Grækenland, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, Grækenland, 411 10
- GSK Investigational Site
-
-
-
-
-
Enschede, Holland, 7512 KZ
- GSK Investigational Site
-
Groningen, Holland, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, Holland, 8934 AD
- GSK Investigational Site
-
Utrecht, Holland, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Avellino, Italien, 83100
- GSK Investigational Site
-
Bergamo, Italien, 24125
- GSK Investigational Site
-
Pisa, Italien, 57124
- GSK Investigational Site
-
Verona, Italien, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, Italien, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Hyōgo, Japan, 673-8558
- GSK Investigational Site
-
Kanagawa, Japan, 241-8515
- GSK Investigational Site
-
Osaka, Japan, 590-0197
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
-
-
-
-
Guadajalara, Mexico, 44280
- GSK Investigational Site
-
San Luis Potosí City, Mexico, 78209
- GSK Investigational Site
-
-
-
-
-
Lublin, Polen, 20-954
- GSK Investigational Site
-
Prabuty, Polen, 82-550
- GSK Investigational Site
-
Siedlce, Polen, 08-110
- GSK Investigational Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- GSK Investigational Site
-
Lisbon, Portugal, 1500-650
- GSK Investigational Site
-
Lisbon, Portugal, 1998-018
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, Portugal, 4434-502
- GSK Investigational Site
-
-
-
-
-
Badajoz, Spanien, 06080
- GSK Investigational Site
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, Spanien, 35016
- GSK Investigational Site
-
Madrid, Spanien, 28041
- GSK Investigational Site
-
Madrid, Spanien, 28046
- GSK Investigational Site
-
Madrid, Spanien, 28027
- GSK Investigational Site
-
Málaga, Spanien, 29010
- GSK Investigational Site
-
PamplonaNavarra, Spanien, 28027
- GSK Investigational Site
-
Valencia, Spanien, 46026
- GSK Investigational Site
-
Valencia, Spanien, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
- GSK Investigational Site
-
-
-
-
-
Cape Town, Sydafrika, 7570
- GSK Investigational Site
-
Parktown, Sydafrika, 2193
- GSK Investigational Site
-
-
-
-
-
Incheon, Sydkorea, 21565
- GSK Investigational Site
-
Seoul, Sydkorea, 03080
- GSK Investigational Site
-
Seoul, Sydkorea, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, Sydkorea, 442-723
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10210
- GSK Investigational Site
-
Chiang Mai, Thailand, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, Thailand, 90110
- GSK Investigational Site
-
Khon Kaen, Thailand, 40002
- GSK Investigational Site
-
Pathum Thani, Thailand, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06800
- GSK Investigational Site
-
Ankara, Tyrkiet (Türkiye), 06680
- GSK Investigational Site
-
Antalya, Tyrkiet (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Tyrkiet (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, Tyrkiet (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13125
- GSK Investigational Site
-
Heidelberg, Tyskland, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Tyskland, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Tyskland, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungarn, H-1121
- GSK Investigational Site
-
Gyöngyös, Ungarn, 3200
- GSK Investigational Site
-
Tatabánya, Ungarn, 2800
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
Eksperimentel: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
Andre navne:
|
|
Eksperimentel: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
Andre navne:
Dostarlimab will be administered
Andre navne:
|
|
Eksperimentel: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
Andre navne:
Dostarlimab will be administered
Andre navne:
|
|
Eksperimentel: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
Andre navne:
Dostarlimab will be administered
Andre navne:
|
|
Eksperimentel: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
Andre navne:
Nelistotug will be administered.
Andre navne:
Dostarlimab will be administered
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med behandling fremkommende bivirkninger (TEAE'er) og alvorlige bivirkninger (SAES)
Tidsramme: Op til 228 uger
|
Op til 228 uger
|
|
Antal deltagere med TEAES eller SAES, der fører til dosismodifikationer eller seponering af behandling
Tidsramme: Op til 228 uger
|
Op til 228 uger
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 213824
- 2021-005115-32 (EudraCT nummer)
- GALAXIES LUNG-201 (Anden identifikator: Study Identifier)
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2023-505057-40-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .